Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry

• Main Authors: Mark Lebwohl (Author), Bruce Strober (Author), Amy Schrader (Author), Alvin H. Li (Author), Thomas Eckmann (Author), Baojin Zhu (Author), William N. Malatestinic (Author), Julie Birt (Author), Meghan Feely (Author), Andrew Blauvelt (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 months. However, newer therapies such as interleukin-...